Template:Isosorbide dinitrate: Difference between revisions
Jump to navigation
Jump to search
No edit summary |
No edit summary |
||
Line 7: | Line 7: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate dosage and administration|Dosage and Administration]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate dosage and administration|Dosage and Administration]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate contraindications|Contraindications]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate contraindications|Contraindications]] | ||
Line 17: | Line 15: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate drug interactions|Drug Interactions]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate drug interactions|Drug Interactions]] | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate overdosage|Overdosage]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate overdosage|Overdosage]] | ||
Line 25: | Line 21: | ||
|- | |- | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate clinical pharmacology|Clinical Pharmacology]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate clinical pharmacology|Clinical Pharmacology]] | ||
! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate clinical studies|Clinical Studies]] | ! style="font-size: 80%; padding: 0 5px; background: #DCDCDC" align=left | [[Isosorbide dinitrate clinical studies|Clinical Studies]] | ||
|- | |- |